FDA authorizes second COVID-19 treatment drug to be used in combination with remdesivir

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) Thursday for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).